While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Nutritional counseling remains a central component of obesity treatment, even in the era of highly effective weight-loss ...

Essentially, Ozempic and Wegovy are brand names for semaglutide, which is in the GLP-1 receptor agonist (GLP-1RA) drug class.

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

NAUSEA, constipation, breathing problems, racing heart… the list of Ozempic side effects appears to be growing by the day.